ArticleEmerging infectious diseases2021
Increase in Kelch 13 Polymorphisms in Plasmodium falciparum, Southern Rwanda.
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Trial
- High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine.The Journal of infectious diseases · 2022Trial
- ATAD3 megadalton complex in Plasmodium falciparum is essential for mitochondrial and cellular viability.PLoS pathogens · 2026Article
- Cross-border molecular epidemiology of Plasmodium falciparum drug susceptibility: insights from the Uganda-Democratic Republic of the Congo border.Malaria journal · 2026Article
- The MARC SE-Africa dashboard: Joining forces to counteract emerging antimalarial resistance in South and East Africa.PLOS digital health · 2026Article
- Potent acridone antimalarial against all three life stages of Plasmodium.Nature communications · 2026Article
- Spatiotemporal antimalarial drug resistance saturation and emerging artemisinin tolerance in western Kenya during a pilot multiple first-line treatment study.Scientific reports · 2026Article
- Functional assessment of prevalentmBio · 2026Article
- Border Region Surveillance of Malaria Drug Resistance, Northern Burundi, 2023-2024.Emerging infectious diseases · 2026Article
- Genomic Surveillance ofPathogens (Basel, Switzerland) · 2025Article
- Strategies for mitigating emerging artemisinin-based antimalarial drug resistance in Rwanda: a promising approach for managing therapies in malaria-endemic countries.BMJ global health · 2025Review
- Investigating the relationship betweenBMJ open · 2025Article
- Malaria: past, present, and future.Signal transduction and targeted therapy · 2025Review
- A Narrative Review on the Prevalence ofTropical medicine and infectious disease · 2025Review
- Half-decade of scaling up malaria control: malaria trends and impact of interventions from 2018 to 2023 in Rwanda.Malaria journal · 2025Review
- Dihydroartemisinin-Piperaquine Combination in the Treatment of UncomplicatedJournal of clinical medicine · 2024Review
- The emergence of artemisinin partial resistance in Africa: how do we respond?The Lancet. Infectious diseases · 2024Review
- Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1.Nature communications · 2024Article
- Therapeutic efficacy and safety of artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria treatment in Metehara, Central-east Ethiopia.Malaria journal · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artemisinin resistance in Plasmodium falciparum is associated with nonsynonymous mutations in the Kelch 13 (K13) propeller domain. We found that 12.1% (8/66) of clinical P. falciparum isolates from Huye district, Rwanda, exhibited K13 mutations, including R561H, a validated resistance marker. K13 mutations appear to be increasing in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.